Alice A. Chen Email & Phone Number

San Mateo, California, Us

Chief Operating Officer (Mar 2024- )Advisor and Fractional COO (Feb 2023-Mar 2024)

Serving health tech startups in their incubation, commercialization and scale-up stages (Seed to Series C)

San Francisco, Ca, Us

Vice Chair of the Board of Directors (May 2023- )Member of the Board of Directors (May 2022-Apr 2023)United Way Bay Area (UWBA) is a deeply established philanthropic organization mobilizing the Bay Area to assist people living in poverty and to dismantle the root causes of poverty. UWBA's programs support individuals seeking employment, families struggling to meet basic needs, and public policy for housing justice. Learn more at www.uwba.org

San Francisco, California , Us

General Inception partners with inventors to ignite innovation and create transformational companies. We are co-founders bringing together domain expertise, seasoned executive talent, infrastructure resources, and capital to nurture company growth from inception. Learn more at https://www.generalinception.com/

Menlo Park, Ca, Us

Menlo Park, Ca, Us

Menlo Park, Ca, Us

GRAIL is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. GRAIL was acquired by Illumina for $8B in a deal that closed in Aug 2021.• Direct reporting responsibilities for product management, program management organization (PMO), portfolio management and customer experience - groups collectively responsible for aligning teams to corporate goals and priorities; developing product roadmaps, business cases, requirements, tradeoff analyses and project plans; and tracking execution to roadmaps/plans. • Executive Chair of product approval committee governing readiness to advance through phases of the product development lifecycle, under design controls meeting regulatory standards. Supported expansion of company product portfolio to include additional cancer detection solutions and new markets. • Executive Sponsor of cross-functional product lifecycle teams responsible for commercial (on-market) and future (in development) versions of Galleri™, GRAIL’s multi-cancer early detection blood test. • Led a cross-functional core team through Galleri™ test definition, test development, analytical validation, clinical validation and launch milestones.

Austin, Texas, Us

Natera is a global leader in providing DNA testing across multiple clinical areas including women's health, organ health, and oncology. Its mission is to change the management of disease by using DNA testing to proactively inform treatment.Director of Product Management (May 2016-Dec 2017)• Oversaw the product strategy, lifecycle management and P&L for Natera’s reproductive health portfolio, including NGS- and microarray-based genetic tests generating >$200M annual revenue (Panorama™ non-invasive prenatal test (NIPT); Vistara™ single gene mutation test; Horizon™ carrier screening; Spectrum™ preimplantation genetic screening/diagnosis (PGS/PGD); Anora™ products of conception test).• Led the evaluation of new product opportunities, prioritization of the product portfolio, and strategic definition of short- and long-term product roadmaps for the reproductive health business. Presented recommendations for achieving aggressive business goals to CEO and Executive Team.• Recruited and directed a team of product managers who helped achieve company’s highest unit growth, launched 6 new products or product enhancements, and initiated 9 new product concepts.Senior Product Manager (May 2015-May 2016)• Defined roadmap and requirements for enhancements to the Horizon™ carrier screen, incorporating customer feedback, market research, reimbursement and pricing strategy and technical feasibility.• Led cross-functional core team to meet key business and product performance indicators (product launch and feature releases, sales, gross margins, customer satisfaction).• Managed external partners and vendors to ensure project milestones were on time and within budget.

New York, New York, Us

Auxogyn is a biotech company and developer of the Eeva™ Test, the first prognostic, non-invasive test for aiding embryo selection in in-vitro fertilization (IVF) procedures. Auxogyn was renamed Progyny in 2015. Progyny raised $130M from its initial public offering (IPO) in Oct 2019 (Nasdaq: PGNY).Director/Head of Biomedical Research (Oct 2013-May 2015)• Led research & scientific affairs supporting Eeva™ (Early Embryo Viability Assessment), the first prognostic, non-invasive test that provides information to help optimize treatment plans for IVF clinicians and their patients. Eeva™ is based on innovations in time-lapse imaging, computer vision and machine learning.• Analyzed competitive trends and defined product roadmap with product marketing. Collected voice-of-customer from healthcare professionals and worked with R&D/Engineering to prioritize product features that improved performance and customer satisfaction.• Managed scientific communication strategy, including publication plan, congress schedule, and key opinion leader (KOL) relationships. Delivered 10 advisor contracts, 8 investigator-sponsored clinical research studies, 2-company sponsored clinical trials, >14 peer-reviewed publications and 34 abstracts.Lead Scientist (Oct 2011-Sep 2013)• Teamed with CEO and founding scientist from Stanford University to build the company’s research & scientific affairs teams. Negotiated strategic research partnerships, recruited scientific talent and managed intellectual property portfolio. Performed competitive analysis and business opportunity due diligence. Acquired non-dilutive grant funding from global pharmaceutical Merck Serono for new product research. • Analyzed clinical and imaging data and authored the first publication of clinical study results that supported CE mark approval, FDA 510(k) de novo clearance & product launch.

Westlake Village, Ca, Us

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Sienna raised $65M from its initial public offering (IPO) in July 2017 (Nasdaq:SNNA).• Partnered with CEO to launch the company Sienna Labs, pitch to investors and recruit advisors.• Co-developed the product pipeline and intellectual property portfolio, with eye to competitive landscape. • Led R&D and first-in-man studies advancing the company’s core technology, Topical Photoparticle Therapy™, for multiple indications in laser skin medicine. Results led to 6 issued US patents and >$86M venture financing.

Cambridge, Ma, Us

• Recruited to work with leadership to formulate one-year and five-year research & development plans, including milestones related to multi-investigator program goals, publications and technology transfer. • Coordinated the writing and submission of 8 grants, 14 manuscripts/theses and other collaboration documents.• Trained post-docs, grad students and staff in experimental planning, data analysis, data visualization and communications.

Cambridge, Ma, Us

• Developed methods to engineer “humanized ectopic artificial livers” and implant and vascularize them in mouse models. Demonstrated feasibility for use in drug development (ADME/Tox), infectious diseases (hepatitis C, malaria) and liver regeneration. • Mentored 5 MIT undergraduates and 1 Harvard undergraduate and coordinated annual KEYS (Keys to Empowering Youth) laboratory workshops.• Recognized by the Wall Street Journal, NPR, National Inventor’s Hall of Fame, Lemelson Foundation, Biomedical Engineering Society and other outlets for scientific innovation.• PhD Thesis Advisor: Professor Sangeeta Bhatia

Livermore, Ca, Us

• Designed and performed experiments to study the mechanism of RNA interference and siRNA delivery. • Recognized with departmental and national awards for teamwork, innovation and performance.

Livermore, Ca, Us

• Developed methods to rapidize PCR and DNA synthesis in handheld microfluidic devices. • Assessed the effects of radiation on chromosomal integrity.

Ph.D., Medical Engineering/Medical Physics (Harvard-Mit Joint Program)

S.M. (Masters Of Science), Engineering Sciences

B.S., Bioengineering